Inozyme Pharma, Inc. (INZY)
|Net Income (ttm)||n/a|
|Trading Day||March 1|
|Day's Range||19.90 - 21.85|
|52-Week Range||16.10 - 31.65|
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of ab...
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency
– U.S. Food and Drug Administration cleared Investigational New Drug Application –
– Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency –
Dr. Johnson Brings More Than 25 Years of Experience in Developing and Implementing Global Regulatory and Clinical Development Strategies from Preclinical Through Product Approval Dr. Johnson B...
– Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs –
Upsized IPO in July 2020 raised $128.8 million in gross proceeds
Inozyme Pharma, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is... [Read more...]
|IPO Date |
Jul 24, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for Inozyme Pharma stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 81.44% from the latest price.